Biofrontera AG (FRA:B8FK) Research & Development: €2.22 Mil (TTM As of Mar. 2026)


FRA:B8FK Biofrontera AG FRA:B8FK
58 GF Score
Price €2.21
GF Value €2.29
Valuation Fairly Valued
! 4 Warning Signs
View Full Analysis

What is Biofrontera AG Research & Development?

Biofrontera AG FRA:B8FK 58 Research & Development is €2.22 Mil as of Mar. 2026. GuruFocus rates FRA:B8FK with a GF Score™ of 58/100 and a GF Value™ of €2.29 (Fairly Valued). The stock has 4 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Biofrontera AG's Research & Development for the three months ended in Mar. 2026 was €0.54 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 was €2.22 Mil.

Biofrontera AG  (FRA:B8FK) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Biofrontera AG Research & Development Related Terms

Biofrontera AG Research & Development Historical Data

* Premium members only.

The historical data trend for Biofrontera AG's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Biofrontera AG Research & Development Chart

Biofrontera AG Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 7.01 7.13 7.85 2.20 2.23

Biofrontera AG Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.55 1.17 1.21 -0.70 0.54
FRA:B8FK
58GF Score
Biofrontera AG FRA:B8FK
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Biofrontera AG Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €2.22 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of €2.22 Mil mean?
Biofrontera AG (FRA:B8FK) has a Research & Development of €2.22 Mil as of Mar. 2026. Research and development expense is the total cost for research and development activities. View historical data on Biofrontera AG and its competitors.
Is Biofrontera AG's Research & Development too high?
Biofrontera AG's current Research & Development is €2.22 Mil. Overall, Biofrontera AG has a GF Score™ of 58/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Biofrontera AG's Research & Development compare to ZTS and UTHR?
Biofrontera AG's Research & Development of €2.22 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Drug Manufacturers company?
A good Research & Development depends on the Drug Manufacturers industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Biofrontera AG and its competitors. Biofrontera AG's current Research & Development is €2.22 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biofrontera AG stock overvalued right now?
Based on GuruFocus' analysis, Biofrontera AG (FRA:B8FK) is currently considered Fairly Valued. The stock's GF Value™ is €2.29, compared to a current price of €2.21 — trading 3.5% below its estimated fair value. The current Research & Development is €2.22 Mil. Biofrontera AG's overall GF Score™ is 58/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Biofrontera AG (FRA:B8FK), the current Research & Development is €2.22 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Biofrontera AG (FRA:B8FK) Overvalued in 2026?

Based on GuruFocus' analysis, Biofrontera AG stock appears to be undervalued. The current stock price of €2.21 is trading 3.5% below its estimated GF Value™ of €2.29. GuruFocus considers Biofrontera AG to be Fairly Valued.

Key valuation signals for FRA:B8FK:

  • Research & Development: €2.22 Mil
  • GF Value™: €2.29 vs. price of €2.21 (3.5% below fair value)
  • GF Score™: 58/100 with 4 warning signs

No single metric tells the full story. See the FRA:B8FK stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Biofrontera AG Business Description

Other Exchanges 0DOL:UKB8FK:Germany
Address Hemmelrather Weg 201, Leverkusen, NW, DEU, 51377
Biofrontera AG is active in the field of healthcare. It manufactures pharmaceutical products, especially medical cosmetics and dermatological drugs for the care and treatment of skin diseases. Its suite of products includes the prescription drugs Ameluz and BF-RhodoLED and BF-RhodoLED XL, for the treatment of actinic keratosis and Belixos, for the regenerative care of reddened and inflamed skin. Geographically, the company generates maximum revenue from Germany, and the rest from Spain, the United Kingdom, the rest of Europe, and other regions.
58GF Score

Get the complete analysis for FRA:B8FK

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€2.21
Price
€2.29
GF Value